Kristen Kluska

Stock Analyst at Cantor Fitzgerald

(4.44)
# 360
Out of 5,022 analysts
241
Total ratings
44.34%
Success rate
31.08%
Average return

Stocks Rated by Kristen Kluska

Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46$63
Current: $49.12
Upside: +28.27%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47$80
Current: $58.96
Upside: +35.69%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $31.69
Upside: +231.33%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $66.11
Upside: +78.49%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $95.29
Upside: -22.34%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23$32
Current: $27.38
Upside: +16.87%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.96
Upside: +84.56%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25$29
Current: $10.49
Upside: +176.45%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.23
Upside: +156.82%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $8.69
Upside: +15.07%
Reiterates: Overweight
Price Target: $30
Current: $6.70
Upside: +347.76%
Maintains: Overweight
Price Target: $163$81
Current: $21.43
Upside: +277.97%
Reiterates: Overweight
Price Target: $7
Current: $5.16
Upside: +35.79%
Maintains: Overweight
Price Target: $67$123
Current: $63.58
Upside: +93.46%
Reiterates: Overweight
Price Target: $90
Current: $2.97
Upside: +2,930.30%
Reiterates: Overweight
Price Target: $7
Current: $1.96
Upside: +257.14%
Maintains: Overweight
Price Target: $99$132
Current: $73.00
Upside: +80.82%
Reiterates: Overweight
Price Target: $25
Current: $14.95
Upside: +67.22%
Reiterates: Overweight
Price Target: $67
Current: $26.46
Upside: +153.21%
Reiterates: Overweight
Price Target: $21
Current: $8.04
Upside: +161.19%
Reiterates: Overweight
Price Target: $29
Current: $14.79
Upside: +96.08%
Initiates: Overweight
Price Target: $17
Current: $6.88
Upside: +147.09%
Initiates: Overweight
Price Target: $8
Current: $2.70
Upside: +196.30%
Reiterates: Overweight
Price Target: $11
Current: $2.52
Upside: +336.51%
Reiterates: Overweight
Price Target: $18
Current: $5.35
Upside: +236.45%
Reiterates: Overweight
Price Target: $14
Current: $1.52
Upside: +821.05%
Reiterates: Overweight
Price Target: $13
Current: $1.79
Upside: +626.26%
Reiterates: Overweight
Price Target: $21
Current: $1.56
Upside: +1,246.15%
Reiterates: Overweight
Price Target: $6
Current: $1.79
Upside: +235.20%
Downgrades: Neutral
Price Target: $90$20
Current: $1.44
Upside: +1,288.89%
Reiterates: Overweight
Price Target: $23
Current: $3.97
Upside: +479.35%
Reiterates: Overweight
Price Target: $900
Current: $1.65
Upside: +54,445.45%
Initiates: Overweight
Price Target: $400
Current: $11.35
Upside: +3,424.23%
Downgrades: Neutral
Price Target: $1,250$85
Current: $0.80
Upside: +10,522.34%
Initiates: Overweight
Price Target: $180
Current: $6.72
Upside: +2,578.57%
Initiates: Overweight
Price Target: $180
Current: $3.45
Upside: +5,117.39%
Downgrades: Neutral
Price Target: $15$11
Current: $1.63
Upside: +574.85%
Initiates: Overweight
Price Target: $60
Current: $1.06
Upside: +5,560.38%
Initiates: Overweight
Price Target: $90
Current: $1.30
Upside: +6,823.08%
Assumes: Overweight
Price Target: $10,620$2,520
Current: $1.44
Upside: +174,900.00%
Initiates: Overweight
Price Target: $160
Current: $0.63
Upside: +25,296.83%